Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced that it has been granted two additional permits by the Australian Government, Department of Health, for the importation of a second shipment of cannabis plant materials for research purposes and the shipment of dried cannabis materials in accordance with the permits. The permits, which have been granted to the Pharmacy Australia Centre of Excellence (“PACE”) at the University of Queensland, enable PACE to import cannabis plant material shipments for research purposes. The company’s Canadian licensed producer partner also obtained the mandatory Canadian permits to export their medical cannabis materials to PACE. The cannabis materials are used for PreveCeutical’s soluble gel (“Sol-gel”) drug delivery research program led by the company’s Chief Research Officer, Dr. Harendra Parekh, for testing various cannabis strains for the development and commercialization of cannabinoid-based Sol-gels.
To view the full press release, visit http://nnw.fm/5iiPV
About PreveCeutical Medical Inc.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the company’s website. For more information about PreveCeutical, please visit www.PreveCeutical.com.
More from NetworkNewsBreaks
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com